Bevacizumab at a lower than standard dose might be effective to treat severe retinopathy of prematurity and possibly reduce the risk for neurodevelopmental delay, according to a study.
Intravenous use of anti-VEGFs has become common practice to treat ROP, but concerns remain about possible adverse effects on the normal development of the brain, lungs, bones, kidneys and retina. The recommended dose of bevacizumab is currently between 0.25 mg and 0.625 mg, the latter being the dose that showed efficacy in the BEAT-ROP trial.
In a masked multicenter study, the Pediatric (Read more...)
Uncategorized